Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease

被引:182
作者
Faucheux, BA
Martin, ME
Beaumont, C
Hauw, JJ
Agid, Y
Hirsch, EC
机构
[1] Hop La Pitie Salpetriere, INSERM, U360, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France
[3] Univ Paris 07, U409, Paris, France
关键词
iron; neuromelanin; Parkinson's disease; redox activity; substantia nigra;
D O I
10.1046/j.1471-4159.2003.01923.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Degeneration of dopaminergic neurones during Parkinson's disease is most extensive in the subpopulation of melanized-neurones located in the substantia nigra pars compacta. Neuromelanin is a dark pigment produced in the dopaminergic neurones of the human substantia nigra and has the ability to bind a variety of metal ions, especially iron. Post-mortem analyses of the human brain have established that oxidative stress and iron content are enhanced in association with neuronal death. As redox-active iron (free Fe2+ form) and other transition metals have the ability to generate highly reactive hydroxyl radicals by a catalytic process, we investigated the redox activity of neuromelanin (NM)-aggregates in a group of parkinsonian patients, who presented a statistically significant reduction (- 70%) in the number of melanized-neurones and an increased non-heme (Fe3+ ) iron content as compared with a group of matched-control subjects. The level of redox activity detected in neuromelanin-aggregates was significantly increased (+ 69%) in parkinsonian patients and was highest in patients with the most severe neuronal loss. This change was not observed in tissue in the immediate vicinity of melanized-neurones. A possible consequence of an overloading of neuromelanin with redox-active elements is an increased contribution to oxidative stress and intraneuronal damage in patients with Parkinson's disease.
引用
收藏
页码:1142 / 1148
页数:7
相关论文
共 41 条
[1]   EPR investigations of the iron domain in neuromelanin [J].
Aime, S ;
Bergamasco, B ;
Biglino, D ;
Digilio, G ;
Fasano, M ;
Giamello, E ;
Lopiano, L .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1997, 1361 (01) :49-58
[2]   Iron metabolism [J].
Aisen, P ;
Wessling-Resnick, M ;
Leibold, EA .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (02) :200-206
[3]   IRON MELANIN INTERACTION AND LIPID-PEROXIDATION - IMPLICATIONS FOR PARKINSONS-DISEASE [J].
BENSHACHAR, D ;
RIEDERER, P ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 57 (05) :1609-1614
[4]   Sequestration of iron by Lewy bodies in Parkinson's disease [J].
Castellani, RJ ;
Siedlak, SL ;
Perry, G ;
Smith, MA .
ACTA NEUROPATHOLOGICA, 2000, 100 (02) :111-114
[5]  
CONNOR JR, 1995, J NEUROCHEM, V65, P717
[6]   The substantia nigra of the human brain - II. Patterns of loss of dopamine-containing neurons in Parkinson's disease [J].
Damier, P ;
Hirsch, EC ;
Agid, Y ;
Graybiel, AM .
BRAIN, 1999, 122 :1437-1448
[7]   INCREASED NIGRAL IRON CONTENT AND ALTERATIONS IN OTHER METAL-IONS OCCURRING IN BRAIN IN PARKINSONS-DISEASE [J].
DEXTER, DT ;
WELLS, FR ;
LEES, AJ ;
AGID, F ;
AGID, Y ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1989, 52 (06) :1830-1836
[8]   ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE-METALS IN PARKINSONS-DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA [J].
DEXTER, DT ;
CARAYON, A ;
JAVOYAGID, F ;
AGID, Y ;
WELLS, FR ;
DANIEL, SE ;
LEES, AJ ;
JENNER, P ;
MARSDEN, CD .
BRAIN, 1991, 114 :1953-1975
[9]   Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins [J].
Double, KL ;
Zecca, L ;
Costi, P ;
Mauer, M ;
Griesinger, C ;
Ito, S ;
Ben-Shachar, D ;
Bringmann, G ;
Fariello, RG ;
Riederer, P ;
Gerlach, M .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (06) :2583-2589
[10]   Influence of neuromelanin on oxidative pathways within the human substantia nigra [J].
Double, KL ;
Ben-Shachar, D ;
Youdim, MBH ;
Zecca, L ;
Riederer, P ;
Gerlach, M .
NEUROTOXICOLOGY AND TERATOLOGY, 2002, 24 (05) :621-628